Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Drospirenone,Estetrol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : OLIC
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lupin partners with Fuji to strengthen women's health portfolio in Vietnam and Philippines
Details : Nextstellis is a novel combination medication comprising of drospirenone (DRSP) and estetrol (E4), indicated for use by women of reproductive age to prevent pregnancy.
Product Name : Nextstellis
Product Type : Hormone
Upfront Cash : Undisclosed
June 12, 2024
Lead Product(s) : Drospirenone,Estetrol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : OLIC
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Drospirenone
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Drospirenone (3 mg) + Ethinyl Estradiol (0.03 mg) Tablets Relative to Yasmin®
Details : Drospirenone is a Hormone drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
January 31, 2024
Lead Product(s) : Drospirenone
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Drospirenone
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Relative to Yaz®
Details : Drospirenone is a Hormone drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
January 31, 2024
Lead Product(s) : Drospirenone
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Estetrol,Drospirenone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Mithra Completes Pediatric Study of ESTELLE® in Adolescent Patients
Details : Estelle (estetrol monohydrate) is an estrogen receptor agonist small molecule drug candidate, which is currently being evaluated in combination with drospirenone for contraception for 12 to 17 years aged females.
Product Name : Estelle
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 20, 2023
Lead Product(s) : Estetrol,Drospirenone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Estetrol,Drospirenone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Fuji Pharma
Deal Size : $45.4 million
Deal Type : Licensing Agreement
Details : Under the agreements, Fuji Pharma obtains the rights to commercialize and advance the develoopment of Estelle, Mithra’s oral contraceptive product candidate based on Estetrol, for the treatment of Japanese patients with dysmenorrhea or endometriosis, i...
Product Name : Estelle
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 23, 2023
Lead Product(s) : Estetrol,Drospirenone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Fuji Pharma
Deal Size : $45.4 million
Deal Type : Licensing Agreement
Lead Product(s) : Drospirenone
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Drospirenone is a Hormone drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
August 14, 2023
Lead Product(s) : Drospirenone
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Estetrol,Drospirenone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Fuji Pharma
Deal Size : $45.4 million
Deal Type : Licensing Agreement
Details : Under the agreements, Fuji Pharma obtains the rights to commercialize and advance the develoopment of Estelle, Mithra’s oral contraceptive product candidate based on Estetrol, for the treatment of Japanese patients with dysmenorrhea or endometriosis, i...
Product Name : Estelle
Product Type : Miscellaneous
Upfront Cash : $29.0 million
August 03, 2023
Lead Product(s) : Estetrol,Drospirenone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Fuji Pharma
Deal Size : $45.4 million
Deal Type : Licensing Agreement
Lead Product(s) : Drospirenone
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Drospirenone is a Hormone drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
July 07, 2023
Lead Product(s) : Drospirenone
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Estetrol,Drospirenone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Mithra Announces Completion of Recruitment in Pediatric Study of Estelle in Adolescent Patients
Details : Estelle® is a novel patent protected combined oral contraceptive pill containing 3 mg drospirenone (DRSP) and 15 mg estetrol (E4). E4 is a naturally produced estrogen during pregnancy, which can now be made from a plant source.
Product Name : Estelle
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 10, 2023
Lead Product(s) : Estetrol,Drospirenone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Drospirenone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Chemo Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females
Details : Drospirenone is a Hormone drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Contraception.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
July 18, 2022
Lead Product(s) : Drospirenone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Chemo Research
Deal Size : Inapplicable
Deal Type : Inapplicable